Some ASTX notes

Dacogen is marketed in >30 countries for treatment of myelodysplastic syndromes.  ASTX receives royalties from its marketing partner, Eisai. In 2011, received approx. $60M in royalties.

Dacogen is currently being assessed for an indication in elderly AML. Phase 3 trial (reported at ASCO) demonstrated an improved survival for a Dacogen group vs. control without any significant increase in morbidity. FDA PDUFA on 3/6/2012. EMA decision expected in Q2 2012.

Company was profitable in 2009 & 2010 and expects to be profitable in 2011.

128M in cash, no debt, cash per share = $1.35.

52 week high – $3.32, low – $1.51

PE ~9

Ave. vol ~300K


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s